Titan Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Titan Pharmaceuticals, Inc. operates primarily as a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products. Its main product offerings encompass pharmaceutical dosage forms including extended-release drug delivery systems, branded pharmaceutical products, and licensing agreements for proprietary drug delivery technologies. The company specifically manufactures and markets products such as Probuphine, an implantable buprenorphine system for opioid dependence, and engages in partnerships to expand its pharmaceutical product portfolio. Titan Pharmaceuticals has geographic operations extending primarily across the United States and international markets through its partnerships and licensing arrangements. Founded in 1983, the company is headquartered in South San Francisco, California. In recent developments, Titan Pharmaceuticals completed a significant merger with Black Titan Corporation and TalenTec Sdn. Bhd., a Malaysian private limited company, in October 2025. This reverse merger represents a strategic restructuring involving the formation of a new holding company under Black Titan Corporation and reflects a major change in corporate leadership and ownership structure. The transaction aims to drive business expansion and leverage synergies between the involved entities. Following this merger, Titan Pharmaceuticals ceased trading independently on the Nasdaq exchange. Earlier in 2024, Titan entered into a merger agreement with KE Sdn. Bhd., a distributor of human capital management solutions in the Asia Pacific region, signaling an increased focus on strategic alliances and geographic business development. Titan’s product line extends to pharmaceutical drugs with a focus on extended-release and implantable technologies, as well as a broad portfolio of branded and generic medications distributed via third-party distributors. The company continues to develop and commercialize innovative pharmaceutical solutions with an emphasis on enhancing patient care through proprietary drug delivery systems and collaborations in new therapeutic areas. Titan Pharmaceuticals is engaged in ongoing efforts to expand its presence and offerings through corporate restructuring, mergers, and strategic partnerships aimed at enhancing shareholder value and operational capabilities.
Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation
TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP
URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock
Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.
Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock
North American Morning Briefing : Global Ad Shares -2-
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNP
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNP
Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
TTNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Titan Pharmaceuticals, Inc. Is Fair to Shareholders
Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
Which Industries Are Penny Stocks Investors Watching Right Now
What to Know About Buying Penny Stocks on July 8th